Whether one is referring to high-profile nanomedicine-based firms or pre-clinical university research, the fact that drug delivery is at the forefront of the fight against cancer bodes well for Nuvilex, which has already demonstrated significant efficacy and low toxicity in its Phase II inoperable pancreatic cancer trials.

Innocap is a great story that has broad appeal among public and private investors and appears poised to now become a great stock. Led by a renowned leader in marine salvage recovery, Innocap offers huge upside via the potential value of marine salvage recovery cargo (i.e., treasure) with the I-52 project potentially worth hundreds of millions alone. Plus, Innocap is poised to enjoy other revenue streams related to post-recovery operations including film production, education, promotion, entertainment and exhibitions.

Clearly, whether EGCG is used alone or in conjunction with L-theanine, cognitive abilities can be aided via consumption of these nutrients. This opens up a whole new market for a company such as Plandaí that has demonstrated an ability to generate substantial bioavailability in botanical extracts, including green tea, which is key in leveraging the huge opportunity with Baby Boomers, the aging, and the younger set, which are prime targets for wellness and cognitive health.

By taking a very slow and steady approach, and focusing on the most critical piece of the acquisition (exclusive license) instead of becoming too big too soon (by acquiring the entity), management executed a great deal for shareholders.

Finding preventive products that health conscious men can routinely utilize will emerge as a way to fight prostate cancer and creates a large opportunity and market for companies such as Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.47 – Spec Buy).

With its infrastructure already in place, and new wells coming online to drive revenue growth and profitability, DBRM may be the most undervalued oil and gas play in the market. The stock trades at a huge discount to its peer group and at least a 50% discount to its PV10 value which measures the present value of future cash flows. We rate these shares Speculative Buy with a $0.95 price target.

Much like green tea was introduced by the East to the West, early studies of green tea’s health benefits were largely conducted in Asia, with significant results. Some of these early human studies have even shown that drinking at least two cups of green tea daily inhibits cancer growth.